Objective: To investigate whether adiposity influences endothelial progenitor cell (EPC) number and colony-forming capacity. Design: Cross-sectional study of normal weight, overweight and obese adult humans. Participants: Sixty-seven sedentary adults (aged 45-65 years): 25 normal weight (body mass index (BMI) p25 kg/m 2 ; 12 males/13 females); 18 overweight (BMI ¼ 25-29.9 kg/m 2 ; 12 males/6 females); and 24 obese (BMI X30 kg/m 2 ; 18 males/6 females). All participants were non-smokers and free of overt cardiometabolic disease. Measurements: Peripheral blood samples were collected and circulating EPC number was assessed by flow cytometry. Putative EPCs were defined as CD45
Introduction
Overweight and obesity are associated with increased rates of cardiovascular morbidity and mortality. 1, 2 Endothelial damage and dysfunction is considered to be a major underlying mechanism for the heightened cardiovascular burden with increased adiposity. For example, alterations in endothelial function associated with overweight and obesity that precede and predispose to atherosclerosis and thrombosis include diminished endothelial vasodilator and fibrinolytic function. 3, 4 Although much attention has focused on factors that contribute to adiposity-related endothelial damage, such as inflammation and oxidative stress, recent studies indicate that endogenous endothelial repair and neovascularization processes also play an important role in vascular health and function.
It is now recognized that endothelial repair/regeneration is not only dependent upon the migration and proliferation of surrounding mature endothelial cells resident in the vascular wall, but also on the availability of circulating endothelial progenitor cells (EPCs). 5 Characterized in 1997 by Asahara et al., 6 EPCs possess the ability to proliferate, migrate, differentiate into mature endothelial cells and incorporate into preexisting and newly-forming blood vessels. [6] [7] [8] [9] Circulating EPCs have also generated interest as a novel biomarker of endothelial function and a prognostic indicator of cardiovascular morbidity and mortality. Two recent clinical studies reported that reduced levels of circulating EPCs independently predict atherosclerotic disease progression and death from cardiovascular causes in patients with established coronary artery disease (CAD). 10, 11 Moreover, after adjusting for disease activity and risk factors, low numbers of circulating EPCs were associated with a four-fold increased risk of a future cardiovascular event. 10 In addition, Kunz et al. 12 reported a strong inverse relation between EPC colony-forming capacity and CAD severity in individuals undergoing diagnostic cardiac catheterization, independent of traditional risk factors. Interestingly, the investigators noted that for every 10 EPC colony-forming unit (CFU) increase, the likelihood of multivessel CAD declined by 20%. Numerical and functional deficits in circulating EPCs have also been linked to restenosis rates and impaired neovascularization after ischemic events.
5,13
Although reduced number and impaired function of EPCs have been linked to a number of pathologies associated with overweight/obesity, such as hypertension, hypercholesterolemia, diabetes and CAD, [14] [15] [16] ; 18 males/6 females). All participants were normotensive (arterial blood pressure p140/90 mm Hg), non-smokers, non-medicated (including vitamins) and free of overt cardiovascular, metabolic, renal and hematologic disease, as assessed by medical history, resting and exercise electrocardiograms, and fasting blood chemistries. Individuals were excluded from the study if they exhibited plasma glucose 47.0 mmol l À1 ; total cholesterol X6.0 mmol l
À1
, LDL (low-density lipoprotein)-cholesterol X4.5 mmol l
, triglycerides X2.5 mmol l
. All participants were sedentary and had not performed regular physical exercise for at least 1 year before the beginning of the study. Female participants were at least 1 year post menopausal and had never taken or had discontinued use of hormone replacement therapy at least 1 year before the start of the study. Prior to participation, all of the participants had the research study and its potential risks and benefits explained fully before providing written informed consent according to the guidelines of the University of Colorado at Boulder. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
Body composition
Body mass was measured to the nearest 0.1 kg using a medical beam balance. Percent body fat was determined by dual energy X-ray absorptiometry ( , Gibco) and streptomycin (100 mg ml À1 , Gibco). Endothelial phenotype of these cells was confirmed by immunofluorescent staining for the uptake of DiI-ac-LDL (Biomedical Technologies Inc., Stoughton, MA, USA) and expression of von Willebrand factor (Dako, Glostrup, Denmark), VE-cadherin, CD31 and VEGFR-2 (Invitrogen, Carlsbad, CA, USA).
EPC number
Circulating putative EPC number was determined by fluorescence-activated cell sorting (FACS) analysis following guidelines recommended by the International Society for Hematotherapy and Graft Engineering. 20 Briefly, 2 Â were analyzed for events that were double positive for VEGFR-2 and CD133 and presented as a percent of total viable mononuclear cells. All samples were analyzed using a FC500 flow cytometer (Beckman Coulter) and the data were analyzed by CXP software.
EPC colony-forming assay Endothelial progenitor cell colony-forming capacity was determined as described earlier by our laboratory and others. 16, 21 Briefly, freshly isolated mononuclear cells were plated on six-well plates coated with human fibronectin (BD Biosciences, San Jose, CA, USA) for 48 h at 37 1C. Thereafter, 5 Â 10 5 non-adherent cells from each participant were seeded onto 24-well fibronectin-coated plates (BD Biosciences). Growth medium was changed every 3 days, and the CFUs were counted in four random wells on day 7 by two independent investigators blinded to sample identification. Only CFUs consisting of multiple thin, flat cells emanating from a central cluster of rounded cells were counted.
Statistical analysis
Group differences were determined by analysis of variance.
Where indicated by a significant F-value, Duncan's post hoc test was performed to compare specific group means. Importantly, no main effects of gender, nor interactions of gender with BMI group, were found in any of the key outcome variables. Therefore, the data were combined and presented together. Relations between variables of interest were assessed by Pearson's correlation coefficient and linear regression analysis. All data are expressed as means±s.e. Statistical significance was set a priori at Po0.05.
Results
Selected participant characteristics are presented in Table 1 . All participants were normotensive, normolipidemic and normoglycemic. By design, body mass and body composition values were significantly higher (Po0.05) in the overweight and obese groups compared with the normal weight group. Although within clinically normal ranges, obese participants showed higher (Po0.05) resting systolic and diastolic blood pressure, and lower (Po0.05) high-density lipoprotein-cholesterol, than the normal weight controls. Obese participants also had significantly higher plasma insulin concentrations and HOMA insulin resistance values compared with both the normal weight and overweight participants. There were no differences among the groups in plasma concentrations of total cholesterol, LDL-cholesterol, triglycerides and glucose. The number of CD45
was B50% lower (Po0.05) in the obese (0.0007 ± 0.0001%) compared with the overweight (0.0016 ± 0.0004%) and normal weight groups (0.0015 ± 0.0003%) (Figure 1) . Similarly, the number of CD45 À /CD34 þ cells was lower (Po0.05) in the obese (0.050±0.006%) compared with overweight (0.089 ± 0.019%) and normal weight participants (0.082 ± 0.008%). There were no significant differences in either CD45
þ cells between the overweight and normal weight participants. The capacity of EPCs to form colonies was lower (B40%; Po0.05) in both the overweight (4 ± 1) and obese (6 ± 1) groups versus the normal weight controls (9±2) (Figure 2 ). There was no significant difference in EPC CFU number between the overweight and obese participants. In the overall study population, there were significant inverse relations between BMI and the number of CD45 
Discussion
The new findings of this study are that: (1) the number of circulating EPCs is lower in obese compared with overweight and normal weight adults; and (2) EPC colony-forming Adiposity and endothelial progenitor cells OJ MacEneaney et al capacity is blunted in overweight and obese adults compared with normal weight adults. To our knowledge, this is the first study to show adiposity-related impairments in EPC number and function in overweight and obese adults free of other cardiometabolic abnormalities.
Many of the cardiovascular complications associated with obesity are due, at least in part, to endothelial damage and/ or dysfunction. 22, 23 Circulating EPCs are considered to be an important hemostatic mechanism for counteracting endothelial injury and the accelerated development of atherosclerosis associated with many cardiovascular risk factors, including obesity. 24 For example, circulating EPC number is inversely related to the extent of carotid stenosis and lower extremity atherosclerosis in obese diabetic patients. 25 Moreover, in patients with CAD, higher numbers of circulating EPCs have been linked to greater myocardial perfusion and vascularization 26, 27 as well as overall better prognosis. 10 To date, earlier investigations evaluating the influence of adiposity on progenitor cell number have been hampered by design limitations involving the presence of multiple cardiovascular risk factors, overt disease and/or medication use, making it difficult to discern the impact of obesity per se on EPC number. 28, 29 In this study, we show that the number of circulating putative EPCs, presented as CD45
þ cells, is close to 50% lower in obese compared with overweight and normal weight adults. The absence of other established cardiometabolic risk factors in our study population suggests a primary negative influence of obesity on EPC number. From a clinical perspective, it is plausible that reduced EPC bioavailability may contribute to the increased incidence of endothelium-related vascular complications and reduced neovascularization with obesity. [30] [31] [32] Interestingly, EPC number was not lower in the overweight compared with the normal weight group. The number of CD45
þ cells in the overweight adults was almost identical to that of the normal weight controls and, in turn, significantly higher than the obese adults. This finding was unexpected considering we have earlier reported no differences in the degree of endothelial vasodilator and fibrinolytic dysfunction between overweight and obese adults similar to those studied herein. 3, 33 Nevertheless, greater number of EPCs in overweight adults may play a role in their lower risk of recurrent coronary events following acute myocardial infarction compared with obese adults of similar age. 34 The mechanisms responsible for the obesity-related reduction in circulating putative EPC number are not clear. Figure 1 Circulating levels of (a) CD45
þ cells in normal weight, overweight and obese adults.
Values are mean±s.e. *Po0.05 vs normal weight and overweight. 
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Although we employed strict inclusion criteria in this study, the obese adults did show higher, even though in clinically normal ranges, levels of blood pressure, plasma insulin and insulin resistance. Thus, it is possible that the cumulative effects of these factors, along with other secondary consequences of excess body fatness, such as oxidative stress and inflammation, creates an environment resulting in higher consumption and/or exhaustion of EPC production. For example, the inflammatory cytokine C-reactive protein, although not measured in this study, is often higher in obese compared with overweight and normal weight adults. 35 C-reactive protein has been shown to promote apoptosis in EPCs in vitro, 36 which could negatively impact circulating EPC number. Differences in body fat distribution between the overweight and obese participants may also have contributed to our findings. Future studies are needed to determine whether differences in visceral and subcutaneous body fat depots influence EPC number.
There are conflicting reports in the literature regarding the appropriate defining criteria for the quantification of EPCs. Circulating EPCs are thought to be primarily derived from hematopoietic stem cells; however, non-hematopoietic mesenchymal stem cells and other monocytic cells from peripheral blood have also been shown to cross-differentiate into functionally active endothelial progenitors, or assume an endothelial-like phenotype. 37, 38 It has been suggested that the best strategy for enumeration is to isolate cells positive for both a hematopoietic stem cell surface membrane protein, such as CD34, and a marker of endothelial lineage, such as VEGFR-2, by flow cytometry. 39 However, the antigen CD34 can also be weakly expressed in mature endothelial cells, 40 that are also present in the circulation. 41 As a result, it has been proposed that the immature hematopoietic stem cell marker CD133 also be used for enumeration. 42, 43 Peichev et al. 40 showed that circulating 44, 46 and that, importantly, have been linked to cardiovascular disease risk and outcome. [47] [48] [49] Given the lack of consensus in enumerating EPCs, our results must be viewed within the context of our antigenic profile. Other enumerating criteria, such as quantifying cells double positive for CD34 and VEGFR-2, may yield different results.
In contrast to circulating EPC number, the number of EPC CFUs was B40% lower in both obese and overweight compared with normal weight adults. To our knowledge, this is the first study to show an adiposity-related reduction in EPC colony-forming capacity. Earlier studies that have failed to find a relation between adiposity and EPC CFUs were either underpowered to detect a difference, 16 or included a study population that was compromised by statin use and documented CAD, 50 factors which have been shown to influence EPC function. 12, 51 Once thought to be a surrogate marker of circulating EPC number, it is now generally accepted that the number of EPC CFUs does not correspond to the number of circulating EPCs measured by flow cytometry. 52, 53 The discrepancy in our results between EPC number (determined by FACS) and the number of CFUs further confirm the lack of association between these two measures. Nevertheless, clinical interest in EPC CFUs has increased due to the consistently observed relation between colony number and both endothelial function 16 and cardiovascular risk in healthy and diseased populations. 12, 21, 54 These findings have prompted its use as a novel cardiovascular biomarker. 11, 55 Whether the number of EPC CFUs in overweight and obese adults is associated with endothelial dysfunction and adverse cardiovascular events remains to be determined. The reasons for the reduced EPC colony formation in overweight and obese compared with normal weight adults are not clear. Recent data indicate that the central clusters of cells that make up these colonies are comprised mainly of CD3 þ /CD31 þ /CXCR4 þ T cells. 56, 57 Thus, it is possible that reduction in this subpopulation of T cells with adiposity is the underlying cause. However, in a currently ongoing study focused on these so-called 'angiogenic T cells,' we have not observed a decline in their number in either overweight or obese adults compared with normal weight controls (unpublished observations). It is important to emphasize that the defining characteristic of an EPC CFU is the presence of spindle-shaped cells emanating from a central cluster of cells. 16 These spindle-shaped cells, more so than the central colony clusters, have been shown to demonstrate immunologic and morphologic characteristics consistent with the identification of putative EPCs. 58 It is possible that the same milieu of factors that negatively affect circulating EPC number in vivo may also impair their ability to contribute to cluster formation in vitro. Indeed, inflammatory and oxidative substances, such as C-reactive protein and oxidized LDL-cholesterol, have been shown to impair EPC function in vitro. 59, 60 In conclusion, the results of the present study indicate that increased body fatness, independent of other traditional Adiposity and endothelial progenitor cells OJ MacEneaney et al cardiovascular risk factors, adversely affects EPC biology. Obesity, but not overweight, is associated with lower levels of circulating EPCs compared with normal weight adults; whereas, both overweight and obesity are associated with blunted EPC colony-forming capacity. Although the differential effects of overweight and obesity on circulating EPCs require more attention, diminished EPC bioavailability and impaired function may contribute to adiposity-related cardiovascular morbidity and mortality.
